Reuters: Global Markets: Omeros' knee surgery drug fails in late-stage study

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Omeros' knee surgery drug fails in late-stage study Dec 27th 2012, 21:52 Thu Dec 27, 2012 4:52pm EST (Reuters) - Omeros Corp (OMER.O) said a late-stage trial of its experimental drug for patients undergoing knee surgery did not meet its main goal, sending the company's shares down as much as 10 percent in extended trade. The company said the drug -- codenamed OMS103HP -- did not meet a patient-reported measure that comprised questions about knee swelling and stiffness. A second late-stage trial on the drug remains on track and will begin in the first half of 2013, said the company that focuses on treating inflammation and disorders of the central nervous system. Omeros's shares were down 6 percent at $5.50 after the bell on Thursday. (Reporting by Prateek Kumar; Editing by Sreejiraj Eluvangal)

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions